These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 6422042

  • 1. N-[5-(trifluoromethyl)-6-methoxy-1-naphthalenyl]thioxomethyl]- N-methylglycine (Tolrestat), a potent, orally active aldose reductase inhibitor.
    Sestanj K, Bellini F, Fung S, Abraham N, Treasurywala A, Humber L, Simard-Duquesne N, Dvornik D.
    J Med Chem; 1984 Mar; 27(3):255-6. PubMed ID: 6422042
    [No Abstract] [Full Text] [Related]

  • 2. The effects of a new aldose reductase inhibitor (tolrestat) in galactosemic and diabetic rats.
    Simard-Duquesne N, Greselin E, Dubuc J, Dvornik D.
    Metabolism; 1985 Oct; 34(10):885-92. PubMed ID: 3930915
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of polyol pathway activity in diabetic and galactosemic rats by the aldose reductase inhibitor CP-45,634.
    Peterson MJ, Sarges R, Aldinger CE, MacDonald DP.
    Adv Exp Med Biol; 1979 Oct; 119():347-56. PubMed ID: 115231
    [No Abstract] [Full Text] [Related]

  • 4. Syntheses of tolrestat analogues containing additional substituents in the ring and their evaluation as aldose reductase inhibitors. Identification of potent, orally active 2-fluoro derivatives.
    Wrobel J, Millen J, Sredy J, Dietrich A, Gorham BJ, Malamas M, Kelly JM, Bauman JG, Harrison MC, Jones LR.
    J Med Chem; 1991 Aug; 34(8):2504-20. PubMed ID: 1908522
    [Abstract] [Full Text] [Related]

  • 5. Prevention of neural myoinositol depletion in diabetic rats by aldose reductase inhibition with tolrestat.
    Kemper C, Dvornik D.
    Proc Soc Exp Biol Med; 1986 Sep; 182(4):505-10. PubMed ID: 3090558
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of aldose reductase activities by kampo medicines.
    Aida K, Shindo H, Tawata M, Onaya T.
    Planta Med; 1987 Apr; 53(2):131-5. PubMed ID: 3110810
    [No Abstract] [Full Text] [Related]

  • 7. Properties of ICI 128,436, a novel aldose reductase inhibitor, and its effects on diabetic complications in the rat.
    Stribling D, Mirrlees DJ, Harrison HE, Earl DC.
    Metabolism; 1985 Apr; 34(4):336-44. PubMed ID: 3920474
    [Abstract] [Full Text] [Related]

  • 8. Computer-assisted design and synthesis of novel aldose reductase inhibitors.
    Butera J, Bagli J, Doubleday W, Humber L, Treasurywala A, Loughney D, Sestanj K, Millen J, Sredy J.
    J Med Chem; 1989 Apr; 32(4):757-65. PubMed ID: 2539477
    [Abstract] [Full Text] [Related]

  • 9. Orally active aldose reductase inhibitors derived from bioisosteric substitutions on tolrestat.
    Wrobel J, Millen J, Sredy J, Dietrich A, Kelly JM, Gorham BJ, Sestanj K.
    J Med Chem; 1989 Nov; 32(11):2493-500. PubMed ID: 2509709
    [Abstract] [Full Text] [Related]

  • 10. [Effects of M79175, an aldose reductase inhibitor, on experimental sugar cataracts].
    Ono H, Nozawa Y, Hayano S.
    Nippon Ganka Gakkai Zasshi; 1982 Nov; 86(9):1343-50. PubMed ID: 6818854
    [No Abstract] [Full Text] [Related]

  • 11. Diabetic cataracts in animal models: prevention and reversibility with aldose reductase inhibitors.
    Kador PF, Akagi Y, Kinoshita JH.
    Diabet Med; 1985 May; 2(3):194-6. PubMed ID: 2952419
    [No Abstract] [Full Text] [Related]

  • 12. Prevention of urinary albumin excretion in 6 month streptozocin-diabetic rats with the aldose reductase inhibitor tolrestat.
    McCaleb ML, Sredy J, Millen J, Ackerman DM, Dvornik D.
    J Diabet Complications; 1988 May; 2(1):16-8. PubMed ID: 2968349
    [Abstract] [Full Text] [Related]

  • 13. Spiro hydantoin aldose reductase inhibitors.
    Sarges R, Schnur RC, Belletire JL, Peterson MJ.
    J Med Chem; 1988 Jan; 31(1):230-43. PubMed ID: 3121857
    [Abstract] [Full Text] [Related]

  • 14. Effects of two new aldose reductase inhibitors, AL-1567 and AL-1576, in diabetic rats.
    Griffin BW, McNatt LG, Chandler ML, York BM.
    Metabolism; 1987 May; 36(5):486-90. PubMed ID: 3106757
    [Abstract] [Full Text] [Related]

  • 15. Susceptibility of aldehyde and aldose reductases of human tissues to aldose reductase inhibitors.
    Srivastava SK, Petrash JM, Sadana IJ, Ansari NH, Partridge CA.
    Curr Eye Res; 1987 May; 2(6):407-10. PubMed ID: 6820339
    [Abstract] [Full Text] [Related]

  • 16. A new approach against sugar cataract through aldose reductase inhibitors.
    Banditelli S, Boldrini E, Vilardo PG, Cecconi I, Cappiello M, Dal Monte M, Marini I, Del Corso A, Mura U.
    Exp Eye Res; 1999 Nov; 69(5):533-8. PubMed ID: 10548473
    [Abstract] [Full Text] [Related]

  • 17. Relative importance of aldose reductase versus nonenzymatic glycosylation on sugar cataract formation in diabetic rats.
    Kador PF, Lee JW, Fujisawa S, Blessing K, Lou MF.
    J Ocul Pharmacol Ther; 2000 Apr; 16(2):149-60. PubMed ID: 10803425
    [Abstract] [Full Text] [Related]

  • 18. Development of potent aldose reductase inhibitors having a hydantoin structure.
    Miwa I, Hirano M, Inagaki K, Belbeoc'h C, Okuda J.
    Biochem Pharmacol; 1987 Sep 01; 36(17):2789-94. PubMed ID: 3115267
    [Abstract] [Full Text] [Related]

  • 19. Study of aldose reductase inhibition in intact lenses by 13C nuclear magnetic resonance spectroscopy.
    Williams WF, Odom JD.
    Science; 1986 Jul 11; 233(4760):223-5. PubMed ID: 3088727
    [Abstract] [Full Text] [Related]

  • 20. Ponalrestat: a potent and selective inhibitor of bovine lens aldose reductase.
    Tuffin DP, Dingle A, Sennitt CM, Mirrlees DJ, Ward WH.
    Prog Clin Biol Res; 1989 Jul 11; 290():221-35. PubMed ID: 2498899
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.